Morgan Stanley’s Biodexa Pharmaceuticals BDRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-14
| Closed | -$924 | – | 8111 |
|
|
2025
Q1 | $924 | Buy |
+14
| New | +$2.45K | ﹤0.01% | 7290 |
|
|
2024
Q4 | – | Sell |
-11
| Closed | -$4.04K | – | 7977 |
|
|
2024
Q3 | $4.04K | Buy |
+11
| New | +$8.43K | ﹤0.01% | 6973 |
|
|
2024
Q2 | – | Hold |
0
| – | – | – | 7767 |
|
|
2024
Q1 | – | Hold |
0
| – | – | – | 7671 |
|
|
2023
Q4 | – | Hold |
0
| – | – | – | 7506 |
|
|
2023
Q3 | – | Hold |
0
| – | – | – | 7459 |
|
|
2023
Q2 | – | Hold |
0
| – | – | – | 7500 |
|
|
2023
Q1 | – | Hold |
0
| – | – | – | 7426 |
|
|
2022
Q4 | – | Hold |
0
| – | – | – | 6783 |
|
|
2022
Q3 | – | Hold |
0
| – | – | – | 6973 |
|
|
2022
Q2 | – | Hold |
0
| – | – | – | 6660 |
|
|
2022
Q1 | – | Hold |
0
| – | – | – | 6038 |
|
|
2021
Q4 | – | Hold |
0
| – | – | – | 6191 |
|
|
2021
Q3 | – | Hold |
0
| – | – | – | 5811 |
|
|
2021
Q2 | – | Hold |
0
| – | – | – | 5816 |
|
|
2021
Q1 | – | Hold |
0
| – | – | – | 5666 |
|
|
2020
Q4 | – | Hold |
0
| – | – | – | 6265 |
|
|
2020
Q3 | – | Hold |
0
| – | – | – | 5402 |
|
|
2019
Q4 | – | Hold |
0
| – | -$15K | – | 6645 |
|
|
2019
Q3 | – | Hold |
0
| – | – | – | 6085 |
|
|
2019
Q2 | – | Hold |
0
| – | – | – | 5459 |
|
|
2016
Q2 | – | Hold |
0
| – | – | – | 6507 |
|
|
2016
Q1 | – | Hold |
0
| – | – | – | 6566 |
|
|
2015
Q4 | – | Hold |
0
| – | – | – | 6662 |
|
Other funds holding BDRX
Morgan Stanley's BDRX Position: Q2 2025 in Review
Morgan Stanley sold out of Biodexa Pharmaceuticals (BDRX) in Q2 2025, closing a stake of 14 shares — an estimated $924 sold.
Morgan Stanley first reported a position in BDRX in Q3 2024 and held it in 2 quarters. The position peaked at $4.04K in Q3 2024. 4 funds tracked by Wall St. Rank hold BDRX as of Q2 2025.
- Morgan Stanley reported no remaining Biodexa Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
- Morgan Stanley sold 14 Biodexa Pharmaceuticals shares in Q2 2025, an estimated $924.
- Morgan Stanley first reported a position in Biodexa Pharmaceuticals in Q3 2024 and held it in 2 quarters.
- Morgan Stanley's Biodexa Pharmaceuticals position peaked at $4.04K in Q3 2024.
- 4 funds tracked by Wall St. Rank held Biodexa Pharmaceuticals as of Q2 2025.
Based on Morgan Stanley's 13F filing for Q2 2025, filed 15 Aug 2025.